Bavarian Nordic ADR BVNRY

$10.19 +0.06 (0.58%)

Valuation

Market cap
2,409,072,000
Revenue TTM
$828,850,000
Net income TTM
$143,260,000
PE ratio
6.58
Forward PE
—
Profit margin
17.28%
Debt to equity
0.00

Trading

Volume
1,600
Avg volume
2,268
Day's range
$10.16 – $10.24
Shares out
237,710,000
Stochastic %K
22%
Beta
1.36
Analysts
Strong Buy
Price target
$62.00

Price

Company profile

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immuni...

Show more

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Industry
Biotechnology
Sector
Healthcare
Phone
45 33 26 83 83
Website
https://www.bavarian-nordic.com
Address
Philip Heymans Alle 3, Hellerup, Denmark

Latest news

No headlines yet.